References
- Ropper A, Samuels M, Klein J, editors., et al. Degenerative diseases of the nervous system. In: Adams and Victor’s Principles of Neurology, 12e. McGraw Hill; 2023.
- Widera EW, Brangman SA, Chin NA. Ushering in a new era of Alzheimer disease therapy. JAMA. 2023;330(6):503. doi: 10.1001/jama.2023.11701
- Larkin HD. First donepezil transdermal patch approved for Alzheimer disease. JAMA. 2022;327(17):1642. doi: 10.1001/jama.2022.6662
- Alhazmi HA, Albratty M. An update on the novel and approved drugs for Alzheimer disease. Saudi Pharm J [Internet]. 2022;30(12):1755–1764. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805975/. doi: 10.1016/j.jsps.2022.10.004
- Zhang X, Lian S, Zhang Y, et al. Efficacy and safety of donepezil for mild cognitive impairment: a systematic review and meta-analysis. Clin Neurol Neurosurg [Internet]. 2022;213:107134. https://pubmed.ncbi.nlm.nih.gov/35078087/
- Majidazar R, Rezazadeh-Gavgani E, Sadigh-Eteghad S, et al. Pharmacotherapy of Alzheimer’s disease: an overview of systematic reviews. Eur J Clin Pharmacol. 2022;78(10):1567–1587. doi: 10.1007/s00228-022-03363-6
- Marucci G, Buccioni M, Ben DD, et al. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology. 2020;190:108352. doi: 10.1016/j.neuropharm.2020.108352
- FDA. ADLARITY- donepezil hydrochloride patch [Internet]. dailymed.nlm.nih.gov. Nih. 2022 [cited 2023 Aug 30]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1cb44c65-00e8-4b5c-99c2-ad15173115a0&type=display
- FDA. DailyMed - RIVASTIGMINE patch [Internet]. dailymed.nlm.nih.gov. 2018 [cited 2024 Apr 8]. Available from: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b671fc9-8cb0-4406-a9ee-7c95086d6200
- FDA. DailyMed - ARICEPT- donepezil hydrochloride tablet, film coated ARICEPT ODT- donepezil hydrochloride tablet, orally disintegrating [Internet]. dailymed.nlm.nih.gov. 2021. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98e451e1-e4d7-4439-a675-c5457ba20975
- Drugs.com | Prescription Drug Information, Interactions & Side Effects [Internet]. Drugs.com. 2011 [cited 2024 Apr 13]. Available from: https://www.drugs.com
- Guo J, Wang Z, Liu R, et al. Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A network meta‐analysis. Brain Behav. 2020;10(11):10. doi: 10.1002/brb3.1831
- Sutthapitaksakul L, Dass CR, Sriamornsak P. Donepezil—an updated review of challenges in dosage form design. J Drug Delivery Sci Technol. 2021;63:102549. doi: 10.1016/j.jddst.2021.102549
- Al Hanbali OA, Khan HMS, Sarfraz M, et al. Transdermal patches: design and current approaches to painless drug delivery. Acta Pharm. 2019;69(2):197–215. doi: 10.2478/acph-2019-0016
- Xu Y, Zhao M, Cao J, et al. Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis. Acta Pharmaceutica Sinica B [Internet]. 2023; Available from: https://www.sciencedirect.com/science/article/pii/S2211383523001703
- Choi J, Choi M-K, Chong S, et al. Effect of fatty acids on the transdermal delivery of donepezil: in vitro and in vivo evaluation. Int J Pharmaceut. 2012;422(1–2):83–90. doi: 10.1016/j.ijpharm.2011.10.031
- Galipoğlu M, Erdal MS, Güngör S. Biopolymer-based transdermal films of Donepezil as an alternative delivery approach in Alzheimer’s disease treatment. AAPS Pharm Sci Tech. 2015;16(2):284–292. doi: 10.1208/s12249-014-0224-6
- Zhou X, Hao Y, Yuan L, et al. Nano-formulations for transdermal drug delivery: a review. Chin Chem Lett [Internet]. 2018;29(12):1713–1724. https://www.sciencedirect.com/science/article/abs/pii/S1001841718304248. doi: 10.1016/j.cclet.2018.10.037
- Mendes IT, Ruela ALM, Carvalho FC, et al. Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of Donepezil. Colloids Surf B Biointerfaces. 2019;177:274–281. doi: 10.1016/j.colsurfb.2019.02.007
- Kodoth AK, Ghate VM, Lewis SA, et al. Pectin-based silver nanocomposite film for transdermal delivery of Donepezil. Int j biol macromol. 2019;134:269–279. doi: 10.1016/j.ijbiomac.2019.04.191
- Islam M, Uddin S, Chowdhury M, et al. Insulin transdermal delivery system for diabetes treatment using a biocompatible ionic liquid-based microemulsion. ACS Appl Mater Inter. 2021;13:42461–42472. doi: 10.1021/acsami.1c11533
- Islam R, Habib Nabila F, Wakabayashi R, et al. Ionic Liquid-Based patch formulation for enhanced transdermal delivery of sparingly soluble drug. J Mol Liq. 2024;397:124184. doi: 10.1016/j.molliq.2024.124184
- Dinh L, Lee S, Abuzar SM, et al. Formulation, preparation, characterization, and evaluation of dicarboxylic ionic liquid donepezil transdermal patches. Pharmaceutics. 2022;14(1):205. doi: 10.3390/pharmaceutics14010205
- Yang J, Liu X, Fu Y, et al. Recent advances of microneedles for biomedical applications: drug delivery and beyond. Acta Pharm Sin B [Internet]. 2019;9(3):469–483. https://www.sciencedirect.com/science/article/pii/S2211383518312437
- Kearney M-C, Caffarel-Salvador E, Fallows SJ, et al. Microneedle-mediated delivery of donepezil: potential for improved treatment options in Alzheimer’s disease. Eur J Pharm Biopharm. 2016;103:43–50. doi: 10.1016/j.ejpb.2016.03.026
- Qiang Zhao Z, Liang L, Fu Hu L, et al. Subcutaneous implantable microneedle system for the treatment of Alzheimer’s disease by delivering Donepezil. Biomacromolecules. 2022;23(12):5330–5339. doi: 10.1021/acs.biomac.2c01155
- Kim J-Y, Han M-R, Kim Y-H, et al. Tip-loaded dissolving microneedles for transdermal delivery of donepezil hydrochloride for treatment of Alzheimer’s disease. Eur J Pharm Biopharm. 2016;105:148–155. doi: 10.1016/j.ejpb.2016.06.006
- Wang Y, Zeng L, Song W, et al. Influencing factors and drug application of iontophoresis in transdermal drug delivery: an overview of recent progress. Drug Delivery and Translational Research [Internet]. 2021 [cited 2021 Dec 14]. Available from: https://link.springer.com/article/10.1007%2Fs13346-021-00898-6
- Kale M, Kipping T, Banga AK. Modulated delivery of donepezil using a combination of skin microporation and iontophoresis. Int J Pharmaceut. 2020;589:119853. doi: 10.1016/j.ijpharm.2020.119853
- Saluja S, Kasha PC, Paturi J, et al. A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. Int J Pharmaceut. 2013;453(2):395–399. doi: 10.1016/j.ijpharm.2013.05.029
- FDA. FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patch [Internet]. FDA. 2020 [cited 2024 Feb 16]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-evaluating-risk-burns-and-scars-zecuity-sumatriptan-migraine-patch#:~:text=July%201%2C%202020%2C%20Update%3A
- Tariot PN, Braeckman R, Oh C. Comparison of steady-state pharmacokinetics of donepezil transdermal delivery system with oral donepezil. J Alzheimers Dis. 2022;90(1):161–172. doi: 10.3233/JAD-220530
- FDA. Enforcement Reports [Internet]. www.accessdata.fda.gov. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020690s042.pdf
- Davis SRM, Murgasova R. Comparison of metabolism of Donepezil in Rat, mini-pig and human, following oral and transdermal administration, and in an in vitro model of human epidermis. J Drug Metab Toxicol. 2012 3;3(4). doi: 10.4172/2157-7609.1000129
- Kim YH, Choi HY, Lim H-S, et al. Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug design develop therapy [Internet]. 2015 [cited 2022 Oct 24];9:1419–1426. https://www.dovepress.com/single-dose-pharmacokinetics-of-the-novel-transdermal-donepezil-patch–peer-reviewed-fulltext-article-DDDT
- Han HJ, Park MY, Park KW, et al. A multinational, multicenter, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of Donepezil transdermal patch in patients with Alzheimer’s disease. J Clin Neurol. 2022 [cited 2023 Jun 13];18(4):428. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262446/pdf/jcn-18-428.pdf.
- Dooley M, Lamb HM. Donepezil. Drugs Aging. 2000;16(3):199–226. doi: 10.2165/00002512-200016030-00005
- Nakamura Y, Kim R, Nishiyama K, et al. Efficacy and safety of a transdermal donepezil patch in patients with mild‐to‐moderate Alzheimer’s disease: A 24‐week, randomized, multicenter, double‐blind, parallel group, non‐inferiority study. Geriatrics Gerontology Int. 2023;23(4):275–281. doi: 10.1111/ggi.14566
- Farlow M, Veloso F, Moline M, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC neurol. 2011;11. doi: 10.1186/1471-2377-11-57
- Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract. 2002;56(6):441–446. doi: 10.1111/j.1742-1241.2002.tb11294.x
- Jones RW, Soininen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer’s disease. Int J Geriat Psychiatry. 2004;19(1):58–67. doi: 10.1002/gps.1038
- Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer’s disease. Brit J Clinical Pharma. 2004 [cited 2019 Mar 11];58(s1):1–8. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2004.01848.x/abstract
- Farlow MR, Alva G, Meng X, et al. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis. Curr Med Res Opin. 2010;26(2):263–269. doi: 10.1185/03007990903434914